

28 October 2024

## **Publication of study showing zero percent infection rate when using XPERIENCE™**

**Next Science Limited** (ASX:NXS) ("Next Science" or "the Company") today announces the publication of a study which found XPERIENCE™ to be efficacious in preventing periprosthetic joint infection (PJI) in patients undergoing primary total knee (TKA) and hip (THA) arthroplasties (joint replacement).

Next Science is a medical technology company focused on commercialising its proprietary XPIO™ suite of products to reduce the impact of biofilm-based infections in human health.

On 17 April 2024, Next Science announced that Dr Ravi Bashyal had released the findings of a retrospective 1,295-patient study<sup>1</sup> which used XPERIENCE™ exclusively in 471 consecutive knee and hip arthroplasties during the calendar year of 2022. The overall rate of Surgical Site Infection (SSI) of the 471-patient cohort was zero percent (0/471) compared to a 0.5% infection rate among the control group (4/824) who were treated with a povidone-iodine (Betadine) solution soak in a standardised protocol.

The study findings have now undergone a peer review process and have been published in the *J Orthopaedic Experience & Innovation*. The article entitled "The Use of a Novel Surgical Irrigant May Be Associated with Decreased Incidence of Surgical Site Infections" by Lohith Vatti, MD, Rohan Gopinath MD, Claire Heshmat, Samantha Lariosa, Sarah Rabbitt and Ravi Bashyal MD can be accessed [here](#).

**Next Science's CEO and Managing Director I.V. Hall said:** "The publication of this study by leading orthopaedic surgeon Dr. Bashyal demonstrates the efficacy of XPERIENCE™ in reducing surgical site infections which remain an important factor in negative patient outcomes. This study adds to the growing body of clinical evidence that will increasingly challenge the standard of care in surgical irrigation. We will continue to work closely with surgeons to conduct clinical research that demonstrates the effectiveness of our products."

**Approved and authorised for release by the Managing Director.**

### **Media & Investor Enquiries**

Françoise Dixon

Phone: +61 412 292 977

Email: [fdixon@nextscience.com](mailto:fdixon@nextscience.com)

---

<sup>1</sup> The 1295-patient study consisted of 471 cases in 2022 and control group of 824 patients.

# NEXT SCIENCE®

## About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: [www.nextscience.com](http://www.nextscience.com)

## Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may” and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involved known and unknown risks uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management and could cause Next Science's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.